Immunic Inc (NASDAQ:IMUX) earlier this week provided an update on its multiple sclerosis (MS) drug, vidofludimus calcium, highlighting its potential to address both inflammation and neuroprotection.
Dr Hella Kohlhof, Immunic's Chief Scientific Officer, explained that the drug works through a dual mode of action—activating Nurr1 for neuroprotection and inhibiting DHODH to reduce inflammation and Epstein-Barr virus reactivation.
The company believes this approach could help slow disability worsening, a major concern for MS patients.
A key upcoming milestone for Immunic is the phase two CALLIPER trial readout, expected in April. The trial is focused on progressive MS, and if results confirm the drug’s neuroprotective effects, it could be the first disease-modifying treatment (DMT) to offer such benefits.
Kohlhof noted that neuroprotection remains the highest unmet medical need in MS, as current treatments largely target inflammation.
Vidofludimus calcium has demonstrated a strong safety and tolerability profile, with a placebo-like adverse event rate and low discontinuation rates. The company also emphasized its convenience as a once-daily oral tablet that does not require treatment monitoring, making it an attractive option for both patients and physicians.
Beyond CALLIPER, Immunic has two parallel phase three ENSURE trials for relapsing MS, with completion expected in 2026. Kohlhof stated that Immunic is among the few companies developing a late-stage oral DMT with a focus on both inflammation and neuroprotection, a key differentiator from existing MS treatments.
With limited treatment options for progressive MS, Immunic sees a significant opportunity in addressing this unmet need. If vidofludimus calcium delivers positive CALLIPER results, it could mark a major breakthrough in MS treatment and provide a new option for patients facing long-term disability.